"","title","geo_accession","status","submission_date","last_update_date","type","channel_count","source_name_ch1","organism_ch1","characteristics_ch1","characteristics_ch1.1","characteristics_ch1.2","characteristics_ch1.3","characteristics_ch1.4","characteristics_ch1.5","growth_protocol_ch1","molecule_ch1","extract_protocol_ch1","label_ch1","label_protocol_ch1","taxid_ch1","hyb_protocol","scan_protocol","description","data_processing","platform_id","contact_name","contact_department","contact_institute","contact_address","contact_city","contact_state","contact_zip/postal_code","contact_country","supplementary_file","data_row_count","age:ch1","gender:ch1","subject group:ch1","subject status:ch1","tissue:ch1","tumor stage:ch1"
"GSM4132313","257015613554_1_2 [S-2-2]","GSM4132313","Public on Mar 30 2020","Oct 21 2019","Mar 30 2020","RNA","1","serum of radiosensitive NPC patient","Homo sapiens","subject status: Nasopharyngeal carcinoma (NPC) patient","subject group: radiosensitive","age: 49y","gender: male","tumor stage: II","tissue: serum","About 5mL of non-coagulant blood was collected from every eligible patient. Serum was isolated by centrifuging at 3000 rpm for 10 min at 4 °C, and stored at −80 °C.","total RNA","RNA was prepared using the TRIzol reagent following the manufacturer's recommendations.  RNA was quantified using a NanoDrop-1000 spectrophotometer and quality was monitored with the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA).","Cy3","Labeled RNAs were heat denatured and hybridized to Agilent miRNA microarray, according to manufacturer's protocol.","9606","According to the Agilent miRNA Microarray Protocol (Agilent Technologies).","After hybridization and post-hybridization washes, slides were scanned immediately in Agilent Microarray Scanner with Surescan High Resolution Technology (Agilent Technologies, Santa Clara, CA).","Serum miRNA expression of NPC","Feature Extraction v10.7.3.1 (Agilent Technologies, CA) software was used to extract all features of the data obtained from the scanned images and Bioconductor software was used to analyze the raw data, which are normalized by quantile normalization.","GPL25134","Kaiguo,,Li","Department of Radiation Oncology","Guangxi Medical University Cancer Hospital","71 Hedi Road","Nanning","Guangxi Zhuang Autonomous Region","530021","China","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM4132nnn/GSM4132313/suppl/GSM4132313_US10313827_257015613554_S01_miRNA_1105_Oct12_1_2.txt.gz","2549","49y","male","radiosensitive","Nasopharyngeal carcinoma (NPC) patient","serum","II"
"GSM4132314","257015613554_1_3 [S-2-3]","GSM4132314","Public on Mar 30 2020","Oct 21 2019","Mar 30 2020","RNA","1","serum of radiosensitive NPC patient","Homo sapiens","subject status: Nasopharyngeal carcinoma (NPC) patient","subject group: radiosensitive","age: 47y","gender: female","tumor stage: II","tissue: serum","About 5mL of non-coagulant blood was collected from every eligible patient. Serum was isolated by centrifuging at 3000 rpm for 10 min at 4 °C, and stored at −80 °C.","total RNA","RNA was prepared using the TRIzol reagent following the manufacturer's recommendations.  RNA was quantified using a NanoDrop-1000 spectrophotometer and quality was monitored with the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA).","Cy3","Labeled RNAs were heat denatured and hybridized to Agilent miRNA microarray, according to manufacturer's protocol.","9606","According to the Agilent miRNA Microarray Protocol (Agilent Technologies).","After hybridization and post-hybridization washes, slides were scanned immediately in Agilent Microarray Scanner with Surescan High Resolution Technology (Agilent Technologies, Santa Clara, CA).","Serum miRNA expression of NPC","Feature Extraction v10.7.3.1 (Agilent Technologies, CA) software was used to extract all features of the data obtained from the scanned images and Bioconductor software was used to analyze the raw data, which are normalized by quantile normalization.","GPL25134","Kaiguo,,Li","Department of Radiation Oncology","Guangxi Medical University Cancer Hospital","71 Hedi Road","Nanning","Guangxi Zhuang Autonomous Region","530021","China","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM4132nnn/GSM4132314/suppl/GSM4132314_US10313827_257015613554_S01_miRNA_1105_Oct12_1_3.txt.gz","2549","47y","female","radiosensitive","Nasopharyngeal carcinoma (NPC) patient","serum","II"
"GSM4132315","257015613554_1_4 [S-2-4]","GSM4132315","Public on Mar 30 2020","Oct 21 2019","Mar 30 2020","RNA","1","serum of radiosensitive NPC patient","Homo sapiens","subject status: Nasopharyngeal carcinoma (NPC) patient","subject group: radiosensitive","age: 34y","gender: male","tumor stage: II","tissue: serum","About 5mL of non-coagulant blood was collected from every eligible patient. Serum was isolated by centrifuging at 3000 rpm for 10 min at 4 °C, and stored at −80 °C.","total RNA","RNA was prepared using the TRIzol reagent following the manufacturer's recommendations.  RNA was quantified using a NanoDrop-1000 spectrophotometer and quality was monitored with the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA).","Cy3","Labeled RNAs were heat denatured and hybridized to Agilent miRNA microarray, according to manufacturer's protocol.","9606","According to the Agilent miRNA Microarray Protocol (Agilent Technologies).","After hybridization and post-hybridization washes, slides were scanned immediately in Agilent Microarray Scanner with Surescan High Resolution Technology (Agilent Technologies, Santa Clara, CA).","Serum miRNA expression of NPC","Feature Extraction v10.7.3.1 (Agilent Technologies, CA) software was used to extract all features of the data obtained from the scanned images and Bioconductor software was used to analyze the raw data, which are normalized by quantile normalization.","GPL25134","Kaiguo,,Li","Department of Radiation Oncology","Guangxi Medical University Cancer Hospital","71 Hedi Road","Nanning","Guangxi Zhuang Autonomous Region","530021","China","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM4132nnn/GSM4132315/suppl/GSM4132315_US10313827_257015613554_S01_miRNA_1105_Oct12_1_4.txt.gz","2549","34y","male","radiosensitive","Nasopharyngeal carcinoma (NPC) patient","serum","II"
"GSM4132316","257015613554_2_1 [S-2-5]","GSM4132316","Public on Mar 30 2020","Oct 21 2019","Mar 30 2020","RNA","1","serum of radiosensitive NPC patient","Homo sapiens","subject status: Nasopharyngeal carcinoma (NPC) patient","subject group: radiosensitive","age: 60y","gender: male","tumor stage: II","tissue: serum","About 5mL of non-coagulant blood was collected from every eligible patient. Serum was isolated by centrifuging at 3000 rpm for 10 min at 4 °C, and stored at −80 °C.","total RNA","RNA was prepared using the TRIzol reagent following the manufacturer's recommendations.  RNA was quantified using a NanoDrop-1000 spectrophotometer and quality was monitored with the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA).","Cy3","Labeled RNAs were heat denatured and hybridized to Agilent miRNA microarray, according to manufacturer's protocol.","9606","According to the Agilent miRNA Microarray Protocol (Agilent Technologies).","After hybridization and post-hybridization washes, slides were scanned immediately in Agilent Microarray Scanner with Surescan High Resolution Technology (Agilent Technologies, Santa Clara, CA).","Serum miRNA expression of NPC","Feature Extraction v10.7.3.1 (Agilent Technologies, CA) software was used to extract all features of the data obtained from the scanned images and Bioconductor software was used to analyze the raw data, which are normalized by quantile normalization.","GPL25134","Kaiguo,,Li","Department of Radiation Oncology","Guangxi Medical University Cancer Hospital","71 Hedi Road","Nanning","Guangxi Zhuang Autonomous Region","530021","China","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM4132nnn/GSM4132316/suppl/GSM4132316_US10313827_257015613554_S01_miRNA_1105_Oct12_2_1.txt.gz","2549","60y","male","radiosensitive","Nasopharyngeal carcinoma (NPC) patient","serum","II"
"GSM4132317","257015613554_2_2 [S-4-1]","GSM4132317","Public on Mar 30 2020","Oct 21 2019","Mar 30 2020","RNA","1","serum of radiosensitive NPC patient","Homo sapiens","subject status: Nasopharyngeal carcinoma (NPC) patient","subject group: radiosensitive","age: 41y","gender: male","tumor stage: IV","tissue: serum","About 5mL of non-coagulant blood was collected from every eligible patient. Serum was isolated by centrifuging at 3000 rpm for 10 min at 4 °C, and stored at −80 °C.","total RNA","RNA was prepared using the TRIzol reagent following the manufacturer's recommendations.  RNA was quantified using a NanoDrop-1000 spectrophotometer and quality was monitored with the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA).","Cy3","Labeled RNAs were heat denatured and hybridized to Agilent miRNA microarray, according to manufacturer's protocol.","9606","According to the Agilent miRNA Microarray Protocol (Agilent Technologies).","After hybridization and post-hybridization washes, slides were scanned immediately in Agilent Microarray Scanner with Surescan High Resolution Technology (Agilent Technologies, Santa Clara, CA).","Serum miRNA expression of NPC","Feature Extraction v10.7.3.1 (Agilent Technologies, CA) software was used to extract all features of the data obtained from the scanned images and Bioconductor software was used to analyze the raw data, which are normalized by quantile normalization.","GPL25134","Kaiguo,,Li","Department of Radiation Oncology","Guangxi Medical University Cancer Hospital","71 Hedi Road","Nanning","Guangxi Zhuang Autonomous Region","530021","China","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM4132nnn/GSM4132317/suppl/GSM4132317_US10313827_257015613554_S01_miRNA_1105_Oct12_2_2.txt.gz","2549","41y","male","radiosensitive","Nasopharyngeal carcinoma (NPC) patient","serum","IV"
"GSM4132318","257015613554_2_3 [S-4-2]","GSM4132318","Public on Mar 30 2020","Oct 21 2019","Mar 30 2020","RNA","1","serum of radiosensitive NPC patient","Homo sapiens","subject status: Nasopharyngeal carcinoma (NPC) patient","subject group: radiosensitive","age: 36y","gender: female","tumor stage: IV","tissue: serum","About 5mL of non-coagulant blood was collected from every eligible patient. Serum was isolated by centrifuging at 3000 rpm for 10 min at 4 °C, and stored at −80 °C.","total RNA","RNA was prepared using the TRIzol reagent following the manufacturer's recommendations.  RNA was quantified using a NanoDrop-1000 spectrophotometer and quality was monitored with the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA).","Cy3","Labeled RNAs were heat denatured and hybridized to Agilent miRNA microarray, according to manufacturer's protocol.","9606","According to the Agilent miRNA Microarray Protocol (Agilent Technologies).","After hybridization and post-hybridization washes, slides were scanned immediately in Agilent Microarray Scanner with Surescan High Resolution Technology (Agilent Technologies, Santa Clara, CA).","Serum miRNA expression of NPC","Feature Extraction v10.7.3.1 (Agilent Technologies, CA) software was used to extract all features of the data obtained from the scanned images and Bioconductor software was used to analyze the raw data, which are normalized by quantile normalization.","GPL25134","Kaiguo,,Li","Department of Radiation Oncology","Guangxi Medical University Cancer Hospital","71 Hedi Road","Nanning","Guangxi Zhuang Autonomous Region","530021","China","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM4132nnn/GSM4132318/suppl/GSM4132318_US10313827_257015613554_S01_miRNA_1105_Oct12_2_3.txt.gz","2549","36y","female","radiosensitive","Nasopharyngeal carcinoma (NPC) patient","serum","IV"
"GSM4132319","257015613554_2_4 [S-4-3]","GSM4132319","Public on Mar 30 2020","Oct 21 2019","Mar 30 2020","RNA","1","serum of radiosensitive NPC patient","Homo sapiens","subject status: Nasopharyngeal carcinoma (NPC) patient","subject group: radiosensitive","age: 64y","gender: female","tumor stage: IV","tissue: serum","About 5mL of non-coagulant blood was collected from every eligible patient. Serum was isolated by centrifuging at 3000 rpm for 10 min at 4 °C, and stored at −80 °C.","total RNA","RNA was prepared using the TRIzol reagent following the manufacturer's recommendations.  RNA was quantified using a NanoDrop-1000 spectrophotometer and quality was monitored with the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA).","Cy3","Labeled RNAs were heat denatured and hybridized to Agilent miRNA microarray, according to manufacturer's protocol.","9606","According to the Agilent miRNA Microarray Protocol (Agilent Technologies).","After hybridization and post-hybridization washes, slides were scanned immediately in Agilent Microarray Scanner with Surescan High Resolution Technology (Agilent Technologies, Santa Clara, CA).","Serum miRNA expression of NPC","Feature Extraction v10.7.3.1 (Agilent Technologies, CA) software was used to extract all features of the data obtained from the scanned images and Bioconductor software was used to analyze the raw data, which are normalized by quantile normalization.","GPL25134","Kaiguo,,Li","Department of Radiation Oncology","Guangxi Medical University Cancer Hospital","71 Hedi Road","Nanning","Guangxi Zhuang Autonomous Region","530021","China","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM4132nnn/GSM4132319/suppl/GSM4132319_US10313827_257015613554_S01_miRNA_1105_Oct12_2_4.txt.gz","2549","64y","female","radiosensitive","Nasopharyngeal carcinoma (NPC) patient","serum","IV"
"GSM4132320","257015613555_1_1 [R-2-1]","GSM4132320","Public on Mar 30 2020","Oct 21 2019","Mar 30 2020","RNA","1","serum of radioresistant NPC patient","Homo sapiens","subject status: Nasopharyngeal carcinoma (NPC) patient","subject group: radioresistant","age: 28y","gender: male","tumor stage: II","tissue: serum","About 5mL of non-coagulant blood was collected from every eligible patient. Serum was isolated by centrifuging at 3000 rpm for 10 min at 4 °C, and stored at −80 °C.","total RNA","RNA was prepared using the TRIzol reagent following the manufacturer's recommendations.  RNA was quantified using a NanoDrop-1000 spectrophotometer and quality was monitored with the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA).","Cy3","Labeled RNAs were heat denatured and hybridized to Agilent miRNA microarray, according to manufacturer's protocol.","9606","According to the Agilent miRNA Microarray Protocol (Agilent Technologies).","After hybridization and post-hybridization washes, slides were scanned immediately in Agilent Microarray Scanner with Surescan High Resolution Technology (Agilent Technologies, Santa Clara, CA).","Serum miRNA expression of NPC","Feature Extraction v10.7.3.1 (Agilent Technologies, CA) software was used to extract all features of the data obtained from the scanned images and Bioconductor software was used to analyze the raw data, which are normalized by quantile normalization.","GPL25134","Kaiguo,,Li","Department of Radiation Oncology","Guangxi Medical University Cancer Hospital","71 Hedi Road","Nanning","Guangxi Zhuang Autonomous Region","530021","China","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM4132nnn/GSM4132320/suppl/GSM4132320_US10313827_257015613555_S01_miRNA_1105_Oct12_1_1.txt.gz","2549","28y","male","radioresistant","Nasopharyngeal carcinoma (NPC) patient","serum","II"
"GSM4132321","257015613555_1_3 [R-4-1]","GSM4132321","Public on Mar 30 2020","Oct 21 2019","Mar 30 2020","RNA","1","serum of radioresistant NPC patient","Homo sapiens","subject status: Nasopharyngeal carcinoma (NPC) patient","subject group: radioresistant","age: 59y","gender: male","tumor stage: IV","tissue: serum","About 5mL of non-coagulant blood was collected from every eligible patient. Serum was isolated by centrifuging at 3000 rpm for 10 min at 4 °C, and stored at −80 °C.","total RNA","RNA was prepared using the TRIzol reagent following the manufacturer's recommendations.  RNA was quantified using a NanoDrop-1000 spectrophotometer and quality was monitored with the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA).","Cy3","Labeled RNAs were heat denatured and hybridized to Agilent miRNA microarray, according to manufacturer's protocol.","9606","According to the Agilent miRNA Microarray Protocol (Agilent Technologies).","After hybridization and post-hybridization washes, slides were scanned immediately in Agilent Microarray Scanner with Surescan High Resolution Technology (Agilent Technologies, Santa Clara, CA).","Serum miRNA expression of NPC","Feature Extraction v10.7.3.1 (Agilent Technologies, CA) software was used to extract all features of the data obtained from the scanned images and Bioconductor software was used to analyze the raw data, which are normalized by quantile normalization.","GPL25134","Kaiguo,,Li","Department of Radiation Oncology","Guangxi Medical University Cancer Hospital","71 Hedi Road","Nanning","Guangxi Zhuang Autonomous Region","530021","China","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM4132nnn/GSM4132321/suppl/GSM4132321_US10313827_257015613555_S01_miRNA_1105_Oct12_1_3.txt.gz","2549","59y","male","radioresistant","Nasopharyngeal carcinoma (NPC) patient","serum","IV"
"GSM4132322","257015613555_2_2 [R-4-4]","GSM4132322","Public on Mar 30 2020","Oct 21 2019","Mar 30 2020","RNA","1","serum of radioresistant NPC patient","Homo sapiens","subject status: Nasopharyngeal carcinoma (NPC) patient","subject group: radioresistant","age: 66y","gender: female","tumor stage: IV","tissue: serum","About 5mL of non-coagulant blood was collected from every eligible patient. Serum was isolated by centrifuging at 3000 rpm for 10 min at 4 °C, and stored at −80 °C.","total RNA","RNA was prepared using the TRIzol reagent following the manufacturer's recommendations.  RNA was quantified using a NanoDrop-1000 spectrophotometer and quality was monitored with the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA).","Cy3","Labeled RNAs were heat denatured and hybridized to Agilent miRNA microarray, according to manufacturer's protocol.","9606","According to the Agilent miRNA Microarray Protocol (Agilent Technologies).","After hybridization and post-hybridization washes, slides were scanned immediately in Agilent Microarray Scanner with Surescan High Resolution Technology (Agilent Technologies, Santa Clara, CA).","Serum miRNA expression of NPC","Feature Extraction v10.7.3.1 (Agilent Technologies, CA) software was used to extract all features of the data obtained from the scanned images and Bioconductor software was used to analyze the raw data, which are normalized by quantile normalization.","GPL25134","Kaiguo,,Li","Department of Radiation Oncology","Guangxi Medical University Cancer Hospital","71 Hedi Road","Nanning","Guangxi Zhuang Autonomous Region","530021","China","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM4132nnn/GSM4132322/suppl/GSM4132322_US10313827_257015613555_S01_miRNA_1105_Oct12_2_2.txt.gz","2549","66y","female","radioresistant","Nasopharyngeal carcinoma (NPC) patient","serum","IV"
"GSM4132323","257015613555_2_3 [R-4-5]","GSM4132323","Public on Mar 30 2020","Oct 21 2019","Mar 30 2020","RNA","1","serum of radioresistant NPC patient","Homo sapiens","subject status: Nasopharyngeal carcinoma (NPC) patient","subject group: radioresistant","age: 44y","gender: male","tumor stage: IV","tissue: serum","About 5mL of non-coagulant blood was collected from every eligible patient. Serum was isolated by centrifuging at 3000 rpm for 10 min at 4 °C, and stored at −80 °C.","total RNA","RNA was prepared using the TRIzol reagent following the manufacturer's recommendations.  RNA was quantified using a NanoDrop-1000 spectrophotometer and quality was monitored with the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA).","Cy3","Labeled RNAs were heat denatured and hybridized to Agilent miRNA microarray, according to manufacturer's protocol.","9606","According to the Agilent miRNA Microarray Protocol (Agilent Technologies).","After hybridization and post-hybridization washes, slides were scanned immediately in Agilent Microarray Scanner with Surescan High Resolution Technology (Agilent Technologies, Santa Clara, CA).","Serum miRNA expression of NPC","Feature Extraction v10.7.3.1 (Agilent Technologies, CA) software was used to extract all features of the data obtained from the scanned images and Bioconductor software was used to analyze the raw data, which are normalized by quantile normalization.","GPL25134","Kaiguo,,Li","Department of Radiation Oncology","Guangxi Medical University Cancer Hospital","71 Hedi Road","Nanning","Guangxi Zhuang Autonomous Region","530021","China","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM4132nnn/GSM4132323/suppl/GSM4132323_US10313827_257015613555_S01_miRNA_1105_Oct12_2_3.txt.gz","2549","44y","male","radioresistant","Nasopharyngeal carcinoma (NPC) patient","serum","IV"
"GSM4132324","257015613555_2_4 [R-4-6]","GSM4132324","Public on Mar 30 2020","Oct 21 2019","Mar 30 2020","RNA","1","serum of radioresistant NPC patient","Homo sapiens","subject status: Nasopharyngeal carcinoma (NPC) patient","subject group: radioresistant","age: 50y","gender: male","tumor stage: IV","tissue: serum","About 5mL of non-coagulant blood was collected from every eligible patient. Serum was isolated by centrifuging at 3000 rpm for 10 min at 4 °C, and stored at −80 °C.","total RNA","RNA was prepared using the TRIzol reagent following the manufacturer's recommendations.  RNA was quantified using a NanoDrop-1000 spectrophotometer and quality was monitored with the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA).","Cy3","Labeled RNAs were heat denatured and hybridized to Agilent miRNA microarray, according to manufacturer's protocol.","9606","According to the Agilent miRNA Microarray Protocol (Agilent Technologies).","After hybridization and post-hybridization washes, slides were scanned immediately in Agilent Microarray Scanner with Surescan High Resolution Technology (Agilent Technologies, Santa Clara, CA).","Serum miRNA expression of NPC","Feature Extraction v10.7.3.1 (Agilent Technologies, CA) software was used to extract all features of the data obtained from the scanned images and Bioconductor software was used to analyze the raw data, which are normalized by quantile normalization.","GPL25134","Kaiguo,,Li","Department of Radiation Oncology","Guangxi Medical University Cancer Hospital","71 Hedi Road","Nanning","Guangxi Zhuang Autonomous Region","530021","China","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM4132nnn/GSM4132324/suppl/GSM4132324_US10313827_257015613555_S01_miRNA_1105_Oct12_2_4.txt.gz","2549","50y","male","radioresistant","Nasopharyngeal carcinoma (NPC) patient","serum","IV"
